Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Hayashi, N ^a   Okanoue, T ^b   Tsubouchi, H ^c   Toyota, J ^d   Chayama, K ^e   Kumada, H ^f  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f TORANOMON HOSPITAL   (Japan)

Author keywords

direct acting antiviral; peginterferon; ribavirin; sustained virological response; treatment failure

Indexed keywords

MP 424; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HEADACHE; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HUMAN; INSOMNIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; SKIN DISEASES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84855860896     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01528.x     Document Type: Article

References (22)

1. World Health Organization. Initiative for vaccine research (IVR). [http://www.who.int/vaccine-research/diseases/viral-cancers/en/index2.html]
2. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695. (Pubitemid 28549142)
3. Kenny-Walsh E,. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-1233. (Pubitemid 29181642)
4. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS,. Meta-analysis: re-treatment of genotype I hepatitis C non-responders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010; 32: 969-983.
8. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628.
9. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
10. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-α2b. Ann Intern Med 2009; 150: 528-540.
11. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
12. Lin C, Kwong AD, Perni RB,. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 3-16. (Pubitemid 43796632)
13. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
14. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
15. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56 (1): 78-84.
16. Simmonds P, Mellor J, Sakuldamrongpanich T, et al. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol 1996; 77: 3013-3024.
17. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009; 39: 1056-1063.
18. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
19. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
20. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
21. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-1197.
22. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 2010; 40: 1063-1071.